FDA
-
-
-
-
-
-
-
Johnson & Johnson reports phase 1b results for prostate cancer drug combo
-
-
-
-
-
-
-
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck canc
-
-
-
-
-
-
-
DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
-
-
-
-
-
-
-
RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
-
-
-
-
-
-
-
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (laz
-
-
-
-
-
-
-
FDA grants traditional approval to daratumumab and hyaluronidase-FIHJ for newly diagnosed light chain amyloidosis
-
-
-
-
-
-
-
FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All
